Healthcare

Racura Oncology (ASX:RAC) has advanced its lead oncology program into human testing after dosing the first patient in its HARNESS-1 clinical trial.

Recce Pharmaceuticals (ASX:RCE) has advanced its diabetic foot infection program into a pivotal Phase 3 development pathway after receiving ethics approval for a protocol amendment.

Argent BioPharma (ASX:RGT) has expanded the global licensing arrangement for CannEpil to include veterinary applications, creating a potential additional royalty pathway alongside the existing human-health opportunity.

SomnoMed (ASX:SOM) has entered a new phase following aLeadershiptransition, the launch of Virtus and a revised FY26 revenue outlook.

Starpharma (ASX:SPL) has strengthened itsBalance Sheetto advance DEP HER2-Lu, its lead radioligand therapy candidate, towards first-in-human clinical testing.

Telix Pharmaceuticals (ASX:TLX) has continued its commercial expansion in radiopharmaceuticals, reporting record quarterly revenue and outlining a pathway towards more than US$1 billion in full-year revenue and other income.

Vitrafy Life Sciences (ASX:VFY) has expanded its presence in the United States blood preservation market through a partnership with Hoxworth Blood Center.